Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Rio Tinto (ADR) (RIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Rio Tinto (ADR) — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Rio Tinto (ADR) trades at $89.87 (market cap $150.32B). The key difference: Rio Tinto (ADR) is far larger — about 52.6× Dyne Therapeutics Inc. Common Stock's market cap, and Rio Tinto (ADR) pays a 5% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Rio Tinto (ADR) for 12 Days on average.
| DYN | RIO | |
|---|---|---|
Market Cap | $2.86B | $150.32B |
Volume | 3,341,579 | 1,444,205 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $112.04 |
52-Week Low | $14.60 | $67.89 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $2.18B | $163.66B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Rio Tinto (RIO) trades at $93.06, down 1.31% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company demonstrates strong profitability with 19.58% net income margin and 19.57% ROE, supported by recent quarterly earnings beats. Recent news highlights operational strength with 27% copper production growth at Oyu Tolgoi and maintained 2026 guidance.
The stock presents a compelling value opportunity with a 12.61 P/E ratio trading below the $103.13 consensus target. However, bearish technical momentum and legal risks from Madagascar contamination claims warrant caution. Analyst sentiment is mixed with 35% buy ratings versus 23% sell recommendations, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Rio Tinto (ADR)
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →
